NAS:STOK (USA)
Business Description
Stoke Therapeutics Inc
NAICS : 325412
SIC : 2834
45 Wiggins Avenue, Bedford, MA, USA, 01730
Compare
Compare
Traded in other countries / regions
0GT.Germany
•
STOK.USA
Description
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 132.51 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.72 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -63.1 | |||||
| 3-Year EPS without NRI Growth Rate | -33.7 | |||||
| 3-Year FCF Growth Rate | -54.2 | |||||
| 3-Year Book Growth Rate | 19.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.38 | |||||
| 9-Day RSI | 51.39 | |||||
| 14-Day RSI | 55.47 | |||||
| 6-1 Month Momentum % | -21.55 | |||||
| 12-1 Month Momentum % | -40.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.46 | |||||
| Quick Ratio | 10.46 | |||||
| Cash Ratio | 9.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1560.62 | |||||
| Net Margin % | -1546.24 | |||||
| ROE % | -41.01 | |||||
| ROA % | -35.05 | |||||
| ROIC % | -537.51 | |||||
| ROC (Joel Greenblatt) % | -1103.59 | |||||
| ROCE % | -37.79 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 114.8 | |||||
| PB Ratio | 3.25 | |||||
| Price-to-Tangible-Book | 3.31 | |||||
| EV-to-EBIT | -4.76 | |||||
| EV-to-Forward-EBIT | -4.77 | |||||
| EV-to-EBITDA | -4.83 | |||||
| EV-to-Forward-EBITDA | -4.8 | |||||
| EV-to-Revenue | 74.38 | |||||
| EV-to-Forward-Revenue | 38.95 | |||||
| EV-to-FCF | -23.49 | |||||
| Price-to-Net-Current-Asset-Value | 3.51 | |||||
| Price-to-Net-Cash | 3.75 | |||||
| Earnings Yield (Greenblatt) % | -20.97 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:STOK
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.231 | ||
| EPS (TTM) ($) | -2.56 | ||
| Beta | 0.57 | ||
| Volatility % | 47.1 | ||
| 14-Day RSI | 55.47 | ||
| 14-Day ATR ($) | 1.520747 | ||
| 20-Day SMA ($) | 17.785 | ||
| 12-1 Month Momentum % | -40.67 | ||
| 52-Week Range ($) | 9.545 - 33.0635 | ||
| Shares Outstanding (Mil) | 39.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Stoke Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||